RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics Holdings Corp. (“Talecris”) (Nasdaq: TLCR) today announced its financial results for the three and nine months ended September 30, 2009 and filed its third quarter Form 10-Q today with the U.S. Securities and Exchange Commission (SEC). Third quarter 2009 net revenue increased by 12.9% to $395.7 million from $350.5 million in the third quarter of 2008. Diluted earnings per share were $0.38 in the third quarter of 2009, which is a 72.7% increase over diluted earnings per share of $0.22 for the third quarter of 2008. Total diluted shares outstanding were 93,911,201 for the third quarter of 2009 compared to diluted shares outstanding of 92,097,404 for the third quarter of 2008.
